GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (STU:B1Q) » Definitions » Total Receivables

NRX Pharmaceuticals (STU:B1Q) Total Receivables : €0.01 Mil (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is NRX Pharmaceuticals Total Receivables?

NRX Pharmaceuticals's Total Receivables for the quarter that ended in Jun. 2024 was €0.01 Mil.


NRX Pharmaceuticals Total Receivables Historical Data

The historical data trend for NRX Pharmaceuticals's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals Total Receivables Chart

NRX Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Receivables
0.68 - 0.01 0.01

NRX Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

NRX Pharmaceuticals Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


NRX Pharmaceuticals Total Receivables Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


NRX Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.

NRX Pharmaceuticals Headlines

No Headlines